ArticleMolecular biology reports2025
Xenobiotic metabolizing gene polymorphisms and their influence on ovarian cancer susceptibility: A Case-Control and an in silico approach.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIdentifying the impact of low-penetrance genes in ovarian cancer (OC) presents a significant challenge. Polymorphisms in xenobiotic metabolism genes (XMGs) have influenced carcinogen detoxification, cancer susceptibility, and treatment response in many cancers, yet their role in OC remains fragmentary. The present study examined the genetic variants in crucial XMGs such as CYP2D6, NQO1, GSTT1, GSTM1, and GSTP1 in 460 subjects (209 OC patients and 251 controls).
methodsPCR-RFLP (CYP2D6, NQO1, and GST-P1) and multiplex-PCR (GSTT1 and GSTM1) were used for genotyping. Logistic regression was employed to evaluate the association of genotypes with OC risk. MDR analysis was used to detect SNP-SNP interactions. Various computational tools were used to assess the impact of variants on protein function, structure, and stability.
resultsThe results revealed that the intermediate metabolizers (GA) of CYP2D6*4 variant conferred a 2-fold elevated OC risk (OR 2.01; 95% CI 1.35-3.01; p = 0.0023). Similarly, for NQO1*2 (P187S) variant, the mutant TT genotype showed a significant association with increased OC risk (OR 2.35; 95% CI 1.25-4.42; p = 0.023). No association of GSTT1, GSTM1, and GSTP1 variants was observed in the present study. However, combinatorial gene analysis using MDR indicated that the AG (GSTP1), TT (NQO1), and GA (CYP2D6) genotypes conferred 18.4-fold increased OC risk (OR 18.42; 95% CI 2.18-155.21; p = 0.007). In silico analyses predicted the functional impact of two missense variants (rs1800566 and rs1695) and the effect on splicing for the CYP2D6*4 splice variant.
conclusionThe present study highlights the association of CYP2D6, GSTP1, and NQO1 variants with elevated risk of OC in South Indian women.
Indexed as
Identifiers
40956391What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.